Sunshine Lake Pharma

Privately held: no public share price · China

Assets

(5 total)
5Total Assets
0Approved
1Phase 3 / Filed
4Phase 1–2 / Early
5Diseases
Quick filter:
Showing 5 of 5 assets
Target & Modality
Phase 3
FLT3Small molecule
Acute Myeloid Leukemia
Phase 2/3
Serotonin transporter/5-HT receptorSmall molecule
Major Depressive Disorder
Phase 1
HIF prolyl hydroxylase domain (PHD1/2/3)Small molecule
Chronic Kidney Disease
Phase 1
—
Chronic Hepatitis B
OlorigliflozinNo recent activity
Phase 1
SGLT2Small molecule
Type 2 Diabetes

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
July 2027 (1)
Mitizodone phosphatePhase 2/3Depressive Disorder, Major
Est. primary completion 2027-07 · NCT04984512 · CT.gov ↗
What to watch
November 2027 (1)
Clifutinib BesylatePhase 3Leukemia, Acute Myeloid (AML)
Est. primary completion 2027-11-30 · NCT05586074 · CT.gov ↗
What to watch
December 2027 (1)
Clifutinib BesylatePhase 1/2Acute Myeloid Leukemia, Adult
Est. primary completion 2027-12-31 · NCT05133882 · CT.gov ↗
What to watch
2028 (1)
February 2028 (1)
HEC53856Phase 2Chemotherapy-induced Anemia, Non-Myeloid Malignancy
Est. primary completion 2028-02 · NCT07891377 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Annual history (2 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$670M———report ↗
View 1 more year
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY———$29Mreport ↗